Record holders are under a legal and ethical obligation to maintain records safely and securely. Doctors often query how long medical records should be retained.
Although the guidance refers to minimum periods for which records must be retained, there may be occasions when records need to be kept for longer.
DES is transmitted to the next generations and can take many years to show some of its side-effects. Therefore and for better understanding and study of endocrine disruptor chemicals, we ask that DES victims records should never be destroyed.
Consequences of diethylstilbestrol during pregnancy; 50 years later still a significant problem
Since the 1940s, diethylstilbestrol (DES) has been administered to about three million pregnant women in the United States and in the Netherlands, between 1947 and 1975, to about 220,000. The most important consequences described are: for DES mothers an increased risk of mammary carcinomas and for DES daughters a 1 in 1000 chance of clear cell adenocarcinoma (CCAC) as well as an increased risk of (pre)malignant abnormalities of the stratified epithelium in the vagina and cervix. In addition to this, DES daughters frequently have developmental disorders of the cervix and corpus uteri. In connection with this fertilisation disorders have been described as well as unfavourable outcomes of pregnancy: more ectopic pregnancies, abortion and premature birth. DES sons exhibit an increased frequency of several benign abnormalities of the genitalia.
The Records/Information Lifecycle image by IGA, July 2016.
US National Library of Medicine National Institutes of Health, pubmed/11530703, 2001 Apr 7.
The DES problem continues to be an important issue. The entire cohort of DES mothers is in the age group with a high risk of mammary carcinoma. The youngest DES daughters will be of childbearing age for at least another 15 years; the risk of ectopic pregnancies and pre-term labour is increased. The oldest DES daughters are now reaching postmenopausal age. The incidence of CCAC of the vagina and cervix in the population is bimodal, with a second peak at older age. It is still unknown if at this age DES daughters will have an increased incidence of these malignancies. From animal experiments it becomes clear that DES administration to pregnant mice results in an increased incidence of genital tumours not only in the second generation but also in the third. This has yet to be investigated in humans and deserves special attention.
The legally imposed destruction of patient files after a period of ten years is a serious threat to patient care and scientific investigation, notably in obstetrics and child medicine.
Diethylstilbestrol (DES) is a synthetic estrogen. It was first produced in London in 1938 and was prescribed from 1945 to 1971 to prevent spontaneous abortions. The earliest studies of DES in pregnant women in the United States were conducted at Harvard University in the late 1940s. Although the studies were criticized because they were conducted without the use of controls, the physicians directing the studies concluded that DES was effective against a variety of pregnancy complications and resulted in a healthier maternal environment. In 1947 the FDA approved new drug applications (NDAs) to market DES for the purpose of preventing miscarriages.
In the 1950s, however, controlled studies of DES in pregnant women yielded different results. At Tulane University, researchers found that more of the DES-treated women had miscarriages and premature births, while the controls had bigger, healthier babies. At the University of Chicago, every pregnant woman at the University’s Lying-In Hospital became part of a clinical trial: one-half were randomized to receive DES and the other half received placebos. None of the women were told they were part of a study, nor were they told what drug they were taking. The study found that twice as many of the DES-treated mothers had miscarriages and small babies. Despite growing evidence that DES was ineffective, for the next 20 years the drug was administered to pregnant women to prevent miscarriage. In 1951 the FDA concluded that DES was safe for use during pregnancy and stopped requiring manufacturers to complete NDAs prior to marketing the drug as a preventive against miscarriage.
In 1971 an article in the New England Journal of Medicine reported that between 1966 and 1971 seven cases of clear-cell adenocarcinoma (CCA) had been found in teenage girls. CCA is an extremely rare cancer, particularly in young women. The common element to these seven cases was that their mothers had taken DES during their pregnancies. In that same year, the FDA contraindicated the use of DES as a miscarriage preventive; but by that time, an estimated 1.5 million babies had been exposed to DES. Thirty thousand were exposed in 1971 alone.
Research has found that DES interferes with the formation of normal genital tissue during fetal development. Many studies have found possible associations between DES exposure and abnormalities in daughters of women who took DES while pregnant. These studies, including one looking at DES daughters whose mothers were involved in the University of Chicago experiments, have found possible associations between DES exposure and vaginal and cervical dysplasia (a type of abnormal tissue that either reverts with time or progresses slowly to cancer); adenosis (glandular proliferation); cervical ridges and cervical erosion; uterine structural abnormalities, such as a T-shape of the endometrial cavity and/or an unusually small uterus; uterine hypoplasia (underdeveloped cells); infertility; menstrual irregularities; ectopic pregnancies; fetal death and premature birth; and breast and reproductive-tract cancers. The pathologic changes were more common in women exposed to high DES doses and those exposed early in gestation. It is estimated that there are almost two million ”DES daughters” now of childbearing age (NIH, 1992).
Injury to male babies, or DES sons, has also been reported. No malignant tumors have been reported, but certain genital and semen abnormalities are more common in men exposed to DES in utero than in men not exposed to DES. These abnormalities include penile bleeding, testicular masses, epididymal cysts, hypoplastic testes, and cryptorchidism (undescended testicle) (NIH, 1992). One article reported that one in three DES sons is sterile. Other authors call for more studies to determine whether the observed abnormalities are correlated with an increased risk of infertility (NIH, 1992).
There have also been allegations of injury to third generations. Two legal actions were initiated on behalf of DES granddaughters who claim that their disabilities were caused by their premature birth, which resulted from damage to their mothers’ reproductive organs from in utero DES exposure (see Enright v. Eli Lilly & Co. and Sorrels v. Eli Lilly & Co.). In addition, one DES son filed a legal action alleging that his teenage daughter’s fatal case of clear-cell adenocarcinoma was caused by his exposure to DES in utero.
In addition to reproductive abnormalities, research in animals has shown that DES may induce certain autoimmune disorders. Two small studies done on humans have shown altered T-cell and natural killer cell function in women exposed in utero to DES, and data from one cohort of “DES daughters” shows an increase in reported incidence of autoimmune diseases. Whether DES exposure is associated with an increased risk of developing an autoimmune disorder is an active area of research (NIH, 1992). Concern over the effects of DES on persons exposed in utero continues to prompt further study. The National Cancer Institute (NCI) recently issued a request for applications (RFA) inviting cooperative agreement applications from investigators to assist NCI in studies of women with DES-associated clear-cell adenocarcinoma of the cervix or vagina (The Blue Sheet, 1993). Another RFA from NCI and the National Institute of Child Health and Human Development (NICHD) invites cooperative agreement applications to develop a national program to inform health professionals and the public on the adverse effects of DES (NIH, 1993). Initial awards for both RFAs were expected to be made in September 1993. In addition, an added $2.9 million in federal funds was recently allocated to fund further studies of health problems in DES sons, as well as in daughters and their mothers.
There have been numerous legal actions initiated by daughters whose mothers were exposed to DES during pregnancy; more than a thousand were pending nationwide as of February 1991. Because over 300 companies manufactured DES according to the same formula and pharmacists often filled prescriptions at random, the chief barrier to recovery for most DES plaintiffs is identifying the manufacturer who supplied the drug that a particular mother ingested. Many of the successful cases have relied on theories of joint and several liability.
There have been two reported cases coming out of the University of Chicago experiments in the 1950s.
In Mink v. University of Chicago, three women filed an action against Eli Lilly, a pharmaceutical company manufacturing DES, and the University of Chicago to recover for their daughters’ development of abnormal cervical cellular formations and for their daughters’ increased risk of vaginal and cervical cancer. They also alleged that they themselves and their sons had suffered reproductive and other abnormalities and an increased cancer risk. In addition, the plaintiffs asked the court to allow them to represent the other women in the experiment who were given DES by certifying their case as a class action. The court declined to certify the case as a class action, but issued an opinion on whether the plaintiffs’ claims of injury to themselves and their daughters had merit.
The plaintiffs claimed they were not told that they were part of an experiment, nor were they informed that they were taking DES. They also claimed that since the DES-cancer link was known by 1971, the manufacturer should be liable for making no effort to warn them until late 1975-1976. The plaintiffs maintained that the University had committed a battery by performing a medical experiment on them without their knowledge. They also asserted that the University had breached a duty to notify them that they had taken DES and that their children should be regularly examined. The plaintiffs claimed that Eli Lilly was strictly liable for the manufacture of a defective and unreasonably dangerous drug.
In a hearing on whether the case should be dismissed, the court held that Eli Lilly had a duty to notify the plaintiffs about the DES risks when the company became aware of them or should have become aware of them. Under Illinois tort law, however, in order for the plaintiffs to recover under theories of breach of duty to warn and in strict liability, they must allege physical injury to themselves. Because the plaintiffs in their complaint cited risk of injury or physical injuries to others (their children) under their claims of breach of duty to warn and strict liability, the court dismissed these complaints.
The court did not dismiss the battery allegations. The court held that performing nonemergency treatment without consent or knowledge is an unauthorized contact with another person, or a battery. The court stated that the resolution of the case would not turn on the issue of informed consent or whether there was incomplete disclosure of risks before consent was obtained; because there was a complete absence of consent, the issue to be resolved was whether the University had committed battery against these women.
The case was settled before trial, and the plaintiffs together received a monetary settlement of $225,000 from the University of Chicago for the battery claim. Although the court declined to certify the case as a class action, attorneys for the plaintiffs were able to get the University to agree to provide some services to the other women and their offspring as part of the settlement agreement. The University agreed to treat, free-of-charge, the daughters of any women involved in the 1950 experiments who develop DES-associated vaginal or cervical cancer. They also agreed to provide free annual or biannual medical exams for all offspring exposed to DES in utero during these experiments (Schultz, 1982).
In the second reported case of DES injury from the University of Chicago experiments, two DES daughters initiated legal action against the University of Chicago and Eli Lilly, alleging their injuries resulted from their mother’s participation in the experiments while they were in utero. The plaintiffs also based their legal claims on theories of battery, strict liability, and breach of duty to warn/lack of informed consent. The case was settled out of court for an undisclosed amount (Wetherill v. University of Chicago).
“ Both Rachel Wetherill (“Wetherill”) and Maureen Rogers (“Rogers”) claim injury by exposure in utero to diethylstilbestrol (“DES”), administered to their mothers as part of a study (the “Study”) conducted by Dr. William Dieckmann (“Dieckmann”) in the early 1950s at the University of Chicago (“University”) hospitals. Each Complaint contains the same three counts:
Both actions have reached the final pretrial order stage and have been added to this Court’s list of cases ready for trial. Each plaintiff has now filed motions in limine:
to declare the relevance of the testimony of Dr. Brian L. Strom (Dr. Strom) to Counts I and II,
to exclude evidence concerning University’s asserted routine practice of obtaining the consent of participants in the Study under Fed.R.Evid. (Rules) 403, 406 and 802.
Dr. Strom‘s proposed testimony is described in the final pretrial order:
He will testify that at the time of plaintiff’s exposure to DES, the University of Chicago … knew, or by the application of reasonable, developed human skill and foresight should have had knowledge of the dangers of DES use. Dr. Strom will also testify that DES was inadequately tested prior to its marketing for treatment of accidents of pregnancy. ” …
” Plaintiffs have brought this action on behalf of themselves and some 1,000 women who were given diethylstilbestrol (“DES”) as part of a medical experiment conducted by the defendants, University of Chicago and Eli Lilly & Company, between September 29, 1950, and November 20, 1952. The drug was administered to the plaintiffs during their prenatal care at the University’s Lying-In Hospital as part of a double blind study to determine the value of DES in preventing miscarriages. The women were not told they were part of an experiment, nor were they told that the pills administered to them were DES. Plaintiffs claim that as a result of their taking DES, their daughters have developed abnormal cervical cellular formations and are exposed to an increased risk of vaginal or cervical cancer. Plaintiffs also allege that they and their sons have suffered reproductive tract and other abnormalities and have incurred an increased risk of cancer.
United States District Court, N.D. Illinois, Eastern Division, Columbia US Law, No. 77 C 1431, March 17, 1978,
Mink v. University of Chicago, U.S. District Court for the Northern District of Illinois, Justicia US Law FSupp/460/713/2093161, 460 F. Supp. 713 (N.D. Ill. 1978) October 13, 1978.
The complaint further alleges that the relationship between DES and cancer was known to the medical community as early as 1971, but that the defendants made no effort to notify the plaintiffs of their participation in the DES experiment until late 1975 or 1976 when the University sent letters to the women in the experiment informing them of the possible relationship between the use of DES in pregnant women and abnormal conditions in the genital tracts of their offspring. The letter asked for information to enable the University to contact the sons and daughters of the plaintiffs for medical examination.
The complaint seeks recovery on three causes of action.
The first alleges that the defendants committed a series of batteries on the plaintiffs by conducting a medical experiment on them without their knowledge or consent. The administration of DES to the plaintiffs without their consent is alleged to be an “offensive invasion of their persons” which has caused them “severe mental anxiety and emotional distress due to the increased risk to their children of contracting cancer and other abnormalities.”
The second count is grounded in products liability and seeks to recover damages from defendant Lilly premised on its manufacture of DES as a defective and unreasonably dangerous drug.
Finally, the plaintiffs allege that the defendants breached their duty to notify plaintiffs that they had been given DES while pregnant and that children born from that pregnancy should consult a medical specialist. Throughout the complaint plaintiffs claim the defendants intentionally concealed the fact of the experiment and information concerning the relationship between DES and cancer from the plaintiffs.
Both defendants have moved to dismiss the complaint for failure to state a claim. We will deny the motions as to the first cause of action, and grant the motions as to the second and third causes of action. ” …
Women and Health Research: Ethical and Legal Issues of Including Women in Clinical Studies: Volume I, Institute of Medicine (US) Committee on Ethical and Legal Issues Relating to the Inclusion of Women in Clinical Studies, NCBI PubMed NBK236538, 1994.
Diethylstilbestrol (DES), synthetic estrogen, was first produced in London in 1938. The earliest studies of DES in pregnant women in the United States were conducted at Harvard University in the late 1940s. Although the studies were criticized because they were conducted without the use of controls, the physicians directing the studies concluded that “DES was effective against a variety of pregnancy complications and resulted in a healthier maternal environment“. In 1947 the FDA approved new drug applications (NDAs) to market DES for the purpose of preventing miscarriages.
In the 1950s, however, controlled studies of DES in pregnant women yielded different results. At Tulane University, researchers found that more of the DES-treated women had miscarriages and premature births, while the controls had bigger, healthier babies. At the University of Chicago, every pregnant woman at the University’s Lying-In Hospital (1,646) was a test subject for a DES experiment without their knowledge or consent, and became part of a clinical trial: one-half were randomized to receive DES and the other half received placebos. None of the women were told they were part of a study, nor were they told what drug they were taking. The study found that twice as many of the DES-treated mothers had miscarriages, premature births, small babies, thereby confirming the finding of a Tulane study that contradicted the original uncontrolled Harvard study which extoled high doses of DES effectiveness against pregnancy complications.
In 1951 the FDA concluded that DES was safe for use during pregnancy and stopped requiring manufacturers to complete NDAs prior to marketing the drug as a preventive against miscarriage.
Despite growing evidence that DES was ineffective and the confirmatory findings of harm, physicians continued prescribing DES for 20 years resulting in numerous birth complications and exposing the unborn daughters and sons of their patients to serious risk of cancers.
Informed Consent: the women in this study did not know that the study was taking place and did not know about the study.
Voluntary Participation: these women did not choose to participate in the study.
Failure to prevent unnecessary harm: the Tulane University study should have been considered before proceeding with this case and ultimately leading to harm.
Self-determination: the women did not have the choice to participate or decline participation in the study.
Declaration of Helsinki Violations
The risk and benefits were not weighed in this study.
The loyalty of the doctor did not lie with the women, but to research and the general population.
The women did not have self-determination prior to or during the study.
The University’s Lying-In Hospital experiment should not have been conducted.
That study violated the Hippocratic Oath, the Nuremberg Code, and the Declaration of Helsinki.
The data results from this study should have been published and used.